arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Axogen, Inc.

AXGN
$46.44 ▲ +2.09 (+4.70%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
66 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

Axogen, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.5B
Dividend Yield
Revenue Growth 23.1%
Op. Margin -3.1%
ROIC -0.7%
FCF / Share $0.12
Trailing P/E
Price / Book 9.7x
FCF Yield 0.3%
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Aug 7, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$69.73M
↑ +23.1%
Net Income Profit after all expenses
$-1.52M
↑ +92.3%
Operating Margin Operating profit as % of sales
-3.1%
↑ +32.9% 22th
FCF / Share Free cash flow per share
$0.12
↑ +600.1%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
21
Returns
33
Financial Health
51
Cash Quality
29

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters